Oxford BioTherapeutics Ltd., a clinical stage oncology company with a pipeline of immuno-oncology (IO) and antibody-drug conjugate (ADC)-based therapies and Kite, a Gilead Company, have announced that they have entered into a research collaboration to evaluate five novel targets for a number of hematologic and solid tumor indications. Through this collaboration, OBT will validate five … Continued
Arecor has announced that partner Inhibrx Inc. is to license a novel enhanced formulation of its proprietary therapeutic candidate, INBRX-101, developed by Arecor using the Company’s patented technology, Arestat™. This is the first license under a multi-product development agreement between two companies with the new formulation developed using Arestat, Arecor’s patented reformulation platform. INBRX-101 is a treatment for … Continued
The test, developed by UK biotech Mologic and manufactured by self-testing firm Biosure, will be available for consumers to buy online from retailers such as Boots and Amazon at the beginning of next month.
The Annual General Meeting (AGM) of Calculus VCT plc (the “Company”) will be held at 11.30am on 3 July 2020. The AGM is an important event in the Company’s corporate calendar, providing an opportunity for shareholders to meet the board and put questions to the directors and the investment manager, as well as enabling shareholders … Continued
The UK Creative Content EIS Fund has invested in Maze Theory, a digital entertainment studio focusing on the creation and development of immersive entertainment experiences across multiple platforms, including Virtual Reality (VR), PC, Console and Mobile. Maze Theory established its reputation with the launch of its first VR game – Doctor Who ‘The Edge of … Continued
The funding round will be used for further expansion into the global workforce management market valued at over £3bn. Free trials of its proprietary solutions are being offered to the NHS to assist in supporting medical teams which are facing exceptionally complex scheduling problems during the COVID-19 crisis. Calculus Capital and Mobeus, which first invested … Continued
Scancell, the developer of novel immunotherapies for the treatment of cancer, has developed a technique where DNA is injected into patients to create T-cells that recognise and destroy cancer cells.
While the global pandemic continues to affect our everyday lives, it is important to adapt quickly to a fast changing environment. Several of our portfolio companies have rapidly pivoted to play their part in the fight against COVID-19, and we would like to highlight their efforts below. Mologic A medical diagnostics firm Omega Diagnostics has CE-Marked … Continued
Scancell Holdings plc, the developer of novel immunotherapies for the treatment of cancer, announces that it has initiated a research programme to develop a vaccine for COVID-19. The project will be led by Professor Lindy Durrant, Chief Scientific Officer and Professor of Cancer Immunotherapy at the University of Nottingham, in collaboration with scientists in the … Continued
Follows successful validation by Liverpool School of Tropical Medicine and St George’s, University of London With manufacturing support from Omega Diagnostics, the laboratory-based test aims to deliver up to 46,000 results per day Health services and key worker communities in the UK and Africa will be prioritised for access Bedfordshire, UK, 20 APRIL 2020: Mologic Ltd, a … Continued
Oxford BioTherapeutics (“OBT”) a clinical stage oncology company with a pipeline of immuno-oncology and antibody drug conjugate-based therapies, announced that Boehringer Ingelheim (“BI”) has selected a second asset to advance into formal IND enabling studies. The asset discovery was enabled by OBT’s proprietary OGAP® target discovery platform. It is one of several assets that have … Continued
Raindog is the production company founded by Oscar®-winning actor Colin Firth and former Sony Music CEO Ged Doherty, now joined by writer/producer Trish D Chetty Building on the platform of a robust award-winning film track-record, Raindog will expand into TV drama, music content and documentaries The UK Creative Content EIS Fund has invested in Raindog … Continued
Starling is one of the UK’s leading digital banks and the campaign marks the first piece of work from the brand’s new agency line-up of Wonderhood Studios and media agency Bountiful Cow. In 2018 Starling became the first mobile bank to launch business accounts, with no monthly fees and an in-app marketplace, allowing business owners … Continued
Food giant Mizkan has announced that Wonderhood Studios will take over its creative account from Mcgarrybowen, focusing on advertising for the firm’s food portfolio. This includes Branston Pickle which is coming up to its 100-year anniversary. Vanni Cataldi, Mizkan’s head of marketing, said: “I was really impressed by Alex [Best, Wonderhood Studios’ chief operating officer] and … Continued
Idea management scaleup Wazoku has made two new senior hires, as the company readies itself for further growth in 2020. Kathryn Layland joins as Chief Revenue Officer (CRO) based in Wazoku’s London HQ, while Alex Butucea arrives as Wazoku’s new Director of Software Engineering, in the company’s Bristol office. Layland has held senior global revenue positions with several AdTech solution providers and has experience of growing and scaling SaaS … Continued
BBC news reported on Foamstream, the herbicide-free weed control product of Weedingtech, and its use across council parks and other public spaces. Leo de Montaignac, Chief Executive of Weedingtech, was quoted in the article: “I think that we’re only just seeing the very start of this market, and I think that over the next couple … Continued
Scancell, the developer of novel immunotherapies for the treatment of cancer, is pleased to announce that it has signed a collaboration and non-exclusive research agreement with a US-based, clinical stage antibody company to assess monoclonal antibodies (mAbs) targeting tumour-associated glycans (TaGs) including those that have been enhanced with Scancell’s proprietary AvidiMab™ technology. This is the … Continued
Important note: Past performance is not indicative of future performance. Tax benefits depend on the individual circumstances of each investor and may be subject to change in the future. 03.01.20 It was the year of Brexit (again), another bruising general election, and trauma in the retail fund industry with the demise of Woodford and the … Continued
Oxford BioTherapeutics Ltd. (“OBT”), a clinical stage oncology company developing antibody-based immuno-oncology therapies, has announced the initiation of the dose-escalation portion of its U.S. Phase I program for OBT076, a CD205 targeting antibody-drug conjugate (ADC), in patients with advanced solid tumours. Dose-escalation is the first part of the Phase I program that includes two U.S. … Continued
Past performance is not indicative of future performance. Tax benefits depend on the individual circumstances of each investor and may be subject to change in the future. Calculus Capital has sold their investment in London-based marketing agency Once Upon a Time (OUAT) in a deal which delivered a 1.8x share price return on investment not … Continued
Calculus Capital are delighted to shortlisted for “Best EIS Fund Manager” at the EISA awards. “The EIS Association Awards denote excellence in a number of EIS/SEIS fields. The Awards will be presented at our Chairman’s Reception at the House of Lords on Tuesday 6th February 2018 to those individuals and companies in the EIS and … Continued
Avvio Co-founder and CEO, Frank Reeves discusses the impact of AI on improving hotel booking rates on the travel technology show. Avvio recently launched Allora, the worlds first booking platform powered by artificial intelligence.
Award winning private equity fund manager Calculus Capital strengthens investment team with senior hire Calculus Capital, the private equity firm and pioneer of Enterprise Investment Scheme (‘EIS’) funds, is pleased to announce the appointment of Alexander Crawford as Investment Director. Alexander has over 20 years’ corporate finance experience, including ten years with Robert Fleming & … Continued
Calculus was proud to support the FT Triathlon, run by our portfolio company Human Race. Well done to Roshan Puri and Claire Cherry who represented Calculus at the event. A special congratulations to our investment analyst Claire who stormed to win the women’s sprint triathlon in an impressive time of 1:27:56 for a 750m swim, … Continued